• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非肌层浸润性膀胱癌进展的预测模型:综述

Prediction models for progression of non-muscle-invasive bladder cancer: A review.

作者信息

Fujii Yasuhisa

机构信息

Department of Urology, Tokyo Medical and Dental University Graduate School, Tokyo, Japan.

出版信息

Int J Urol. 2018 Mar;25(3):212-218. doi: 10.1111/iju.13509. Epub 2017 Dec 16.

DOI:10.1111/iju.13509
PMID:29247553
Abstract

An accurate prediction of progression is critically important in the management of non-muscle-invasive bladder cancer. At present, three risk models are widely known for prediction of the risk of tumor recurrence and progression of non-muscle-invasive bladder cancer: the European Organization for Research and Treatment of Cancer, Club Urológico Español de Tratamiento Oncológico, and new European Organization for Research and Treatment of Cancer models. Bladder neck involvement has been shown to be one of the significant predictors for progression in non-muscle-invasive bladder cancer, and a new scoring model (Tokyo Medical and Dental University model) consisting of bladder neck involvement, tumor grade, and stage has been developed and externally validated. However, the predictive abilities of these models are still unsatisfactory, and more precise models are necessary for accurate individual prediction of prognosis. Until now, time-fixed analysis has been used for most studies predicting the prognosis and outcome of non-muscle-invasive bladder cancer patients. In order to predict progression more precisely, time-dependent models should be developed using multiple-event analytical techniques, as non-muscle-invasive bladder cancer often progresses to muscle-invasive bladder cancer after multiple recurrences and changes in tumor characteristics over a long natural history. Integration of molecular markers is also a promising approach. A validated model that accurately predicts the risk of progression would help urologists and patients decide whether and when to choose radical cystectomy on an individual basis.

摘要

准确预测疾病进展对于非肌层浸润性膀胱癌的管理至关重要。目前,有三种风险模型广为人知,可用于预测非肌层浸润性膀胱癌的肿瘤复发和进展风险:欧洲癌症研究与治疗组织(European Organization for Research and Treatment of Cancer)模型、西班牙肿瘤泌尿学俱乐部(Club Urológico Español de Tratamiento Oncológico)模型和新的欧洲癌症研究与治疗组织模型。膀胱颈受累已被证明是非肌层浸润性膀胱癌进展的重要预测因素之一,一种由膀胱颈受累、肿瘤分级和分期组成的新评分模型(东京医科齿科大学模型)已被开发并进行了外部验证。然而,这些模型的预测能力仍不尽人意,需要更精确的模型来准确地对个体预后进行预测。到目前为止,大多数预测非肌层浸润性膀胱癌患者预后和结局的研究都采用了固定时间分析。为了更精确地预测疾病进展,应使用多事件分析技术开发时间依赖性模型,因为非肌层浸润性膀胱癌在多次复发以及肿瘤特征在漫长的自然病程中发生变化后,往往会进展为肌层浸润性膀胱癌。整合分子标志物也是一种很有前景的方法。一个能够准确预测进展风险的经过验证的模型将有助于泌尿科医生和患者决定是否以及何时选择根治性膀胱切除术。

相似文献

1
Prediction models for progression of non-muscle-invasive bladder cancer: A review.非肌层浸润性膀胱癌进展的预测模型:综述
Int J Urol. 2018 Mar;25(3):212-218. doi: 10.1111/iju.13509. Epub 2017 Dec 16.
2
Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in a United States Population.预测美国人群中非肌肉浸润性膀胱癌的复发和进展。
J Urol. 2017 Oct;198(4):824-831. doi: 10.1016/j.juro.2017.04.077. Epub 2017 Apr 19.
3
Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer.细胞周期标志物并不能提高欧洲癌症研究与治疗组织(EORTC)和CUETO风险模型在预测非肌层浸润性高级别膀胱癌复发和进展方面的鉴别能力。
Urol Oncol. 2016 Nov;34(11):485.e7-485.e14. doi: 10.1016/j.urolonc.2016.05.014. Epub 2016 Sep 13.
4
Risk Stratification Tools and Prognostic Models in Non-muscle-invasive Bladder Cancer: A Critical Assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel.非肌层浸润性膀胱癌的风险分层工具和预后模型:欧洲泌尿外科学会非肌层浸润性膀胱癌指南小组的批判性评估。
Eur Urol Focus. 2020 May 15;6(3):479-489. doi: 10.1016/j.euf.2018.11.005. Epub 2018 Nov 22.
5
Management of high-risk non-muscle invasive bladder cancer.高危非肌层浸润性膀胱癌的管理
Minerva Urol Nefrol. 2012 Dec;64(4):255-60.
6
Histological and immunohistochemical markers for progression prediction in transurethrally resected high-grade non-muscle invasive bladder cancer.经尿道切除的高级别非肌层浸润性膀胱癌进展预测的组织学和免疫组化标志物
Int J Clin Exp Pathol. 2015 Jan 1;8(1):743-50. eCollection 2015.
7
Impact of bladder neck involvement on progression in patients with primary non-muscle invasive bladder cancer: a prospective validation study.膀胱颈受累对原发性非肌层浸润性膀胱癌患者疾病进展的影响:一项前瞻性验证研究。
Urol Oncol. 2014 Jan;32(1):38.e29-36. doi: 10.1016/j.urolonc.2013.04.001. Epub 2013 May 20.
8
Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.再次经尿道膀胱肿瘤切除术(re-cTURBT)作为pT1期高级别(HG)疾病复发和进展的风险指标是否有用?一项单中心经验。
Arch Ital Urol Androl. 2017 Dec 31;89(4):272-276. doi: 10.4081/aiua.2017.4.272.
9
[Radical cystectomy in the treatment of bladder cancer always in due time?].[根治性膀胱切除术治疗膀胱癌总是时机恰当吗?]
Urologe A. 2007 Aug;46(8):913-9. doi: 10.1007/s00120-007-1361-2.
10
Survival rates after radical cystectomy according to tumor stage of bladder carcinoma at first presentation.首次就诊时根据膀胱癌肿瘤分期的根治性膀胱切除术后生存率。
Urol Int. 2004;72(2):103-11. doi: 10.1159/000075962.

引用本文的文献

1
Inflammation as a key mediator: linking triglyceride-glucose index to prognosis in non-muscle-invasive bladder cancer.炎症作为关键介质:将甘油三酯-葡萄糖指数与非肌层浸润性膀胱癌的预后相联系
Front Oncol. 2025 May 23;15:1545985. doi: 10.3389/fonc.2025.1545985. eCollection 2025.
2
AI predicting recurrence in non-muscle-invasive bladder cancer: systematic review with study strengths and weaknesses.人工智能预测非肌层浸润性膀胱癌复发:具有研究优缺点的系统评价
Front Oncol. 2025 Jan 7;14:1509362. doi: 10.3389/fonc.2024.1509362. eCollection 2024.
3
Prognostic value of the triglyceride-glucose index in non-muscle-invasive bladder cancer: a retrospective study.
甘油三酯-葡萄糖指数在非肌层浸润性膀胱癌中的预后价值:一项回顾性研究。
Front Nutr. 2024 Dec 16;11:1472104. doi: 10.3389/fnut.2024.1472104. eCollection 2024.
4
An Association Study of Germline Variants in Bladder Cancer-Related Genes with the Prognosis of Non-Muscle Invasive Bladder Cancer.膀胱癌相关基因种系变异与非肌层浸润性膀胱癌预后的关联研究
Bladder Cancer. 2023 Mar 31;9(1):59-71. doi: 10.3233/BLC-220076. eCollection 2023.
5
Radiomics nomogram for predicting disease-free survival after partial resection or radical cystectomy in patients with bladder cancer.膀胱癌患者行部分切除术或根治性膀胱切除术的无病生存预测放射组学列线图。
Br J Radiol. 2024 Jan 23;97(1153):201-209. doi: 10.1093/bjr/tqad010.
6
Development and validation of a clinical prediction model for the risk of distal metastasis in intrahepatic cholangiocarcinoma: a real-world study.开发和验证用于预测肝内胆管细胞癌远处转移风险的临床预测模型:一项真实世界研究。
BMC Gastroenterol. 2024 Jan 2;24(1):1. doi: 10.1186/s12876-023-03084-9.
7
Critical Appraisal of Decision Models Used for the Economic Evaluation of Bladder Cancer Screening and Diagnosis: A Systematic Review.用于膀胱癌筛查和诊断的经济评估的决策模型的批判性评价:系统评价。
Pharmacoeconomics. 2023 Jun;41(6):633-650. doi: 10.1007/s40273-023-01256-9. Epub 2023 Mar 8.
8
Preoperative Systemic Inflammatory Markers as a Significant Prognostic Factor After TURBT in Patients with Non-Muscle-Invasive Bladder Cancer.术前全身炎症标志物作为非肌层浸润性膀胱癌患者经尿道膀胱肿瘤电切术后的重要预后因素
J Inflamm Res. 2023 Jan 21;16:283-296. doi: 10.2147/JIR.S393511. eCollection 2023.
9
Development and external validation of a novel nomogram model for predicting postoperative recurrence-free survival in non-muscle-invasive bladder cancer.开发并验证一种新型列线图模型预测非肌层浸润性膀胱癌术后无复发生存率
Front Immunol. 2022 Nov 15;13:1070043. doi: 10.3389/fimmu.2022.1070043. eCollection 2022.
10
Downregulation of BLM RecQ helicase inhibits proliferation, promotes the apoptosis and enhances the sensitivity of bladder cancer cells to cisplatin.BLM RecQ 解旋酶下调抑制膀胱癌细胞增殖,促进其凋亡,并增强其对顺铂的敏感性。
Mol Med Rep. 2022 Oct;26(4). doi: 10.3892/mmr.2022.12829. Epub 2022 Aug 25.